Biocryst Pharmaceuticals (BCRX) Long-Term Deferred Tax (2017)

Biocryst Pharmaceuticals' Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $5.9 billion for Q4 2017.

• Quarterly Long-Term Deferred Tax changed N/A year-over-year to $5.9 billion in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $5.9 billion (changed N/A YoY) and the FY2017 annual result came in at $5.9 billion, changed N/A from the prior year.
• Long-Term Deferred Tax was $5.9 billion for Q4 2017 at Biocryst Pharmaceuticals, up from $5.9 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $5.9 billion in Q4 2017 and bottomed at $5.9 million in Q1 2017.